

Sotir T Marchev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2036189/publications.pdf>

Version: 2024-02-01

18
papers

31,607
citations

586496

16
h-index

993246

17
g-index

18
all docs

18
docs citations

18
times ranked

27297
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Case: SARS-CoV-2 Reactivation After a Heavy Workout. <i>Acta Medica Bulgarica</i> , 2020, 47, 38-40.	0.0	0
2	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
3	Takayasu Arteritis – A Systematic Review. <i>Acta Medica Bulgarica</i> , 2019, 46, 56-64.	0.0	6
4	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
5	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	13.9	1,099
6	Novel Mitochondria-Targeting Peptide in Heart Failure Treatment. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	125
7	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
8	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
9	Angiotensin – Neprilysin Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	13.9	5,052
10	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
11	Treatment of Anemia with Darbeoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
12	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED-CHF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
13	Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. <i>Lancet Neurology</i> , The, 2012, 11, 315-322.	4.9	310
14	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
15	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet</i> , The, 2010, 376, 875-885.	6.3	2,119
16	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	13.9	6,019
17	Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet</i> , The, 2009, 374, 29-38.	6.3	611
18	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>New England Journal of Medicine</i> , 2008, 359, 2195-2207.	13.9	5,712